| emiplacel (PLX-PAD) / Pluri, Charite - University of Medicine Berlin |
NCT03006770 / 2015-005532-18: Efficacy, Tolerability and Safety of Intramuscular Injections of PLX PAD for the Treatment of Subjects With Critical Limb Ischemia (CLI) With Minor Tissue Loss Who Are Unsuitable for Revascularization |
|
|
| Active, not recruiting | 3 | 213 | Europe, US, RoW | PLX-PAD, Placebo | Pluristem Ltd. | Critical Limb Ischemia (CLI) | 03/21 | 03/21 | | |
| Completed | 3 | 240 | Europe, US, RoW | PLX-PAD, Placebo | Pluristem Ltd. | Hip Fracture | 04/22 | 09/23 | | |
NCT04614025: Open-label Multicenter Study to Evaluate the Efficacy of PLX-PAD for the Treatment of COVID-19 |
|
|
| Terminated | 2a | 23 | Europe, RoW | PLX-PAD | Pluristem Ltd. | COVID, ARDS | 08/21 | 02/23 | | |
2011-004091-12: A Clinical Study to Evaluate the Safety and Efficacy of Injections of Cells from another person for the Treatment of Subjects with Intermittent Claudication (IC). |
|
|
| Ongoing | 2 | 150 | Europe | PLX-PAD, adherent stromal cells (ASC), Suspension for injection | Pluristem Ltd., Pluristem Ltd. | Intermittent Claudication (IC); Fontaine class IIb; Rutherford category 2-3, Intermittent Claudication (IC) (Peripheral arterial occlusive disease); Fontaine class IIb; Rutherford category 2-3, Diseases [C] - Cardiovascular Diseases [C14] | | | | |
NCT04389450: Double-Blind, Multicenter, Study to Evaluate the Efficacy of PLX PAD for the Treatment of COVID-19 |
|
|
| Terminated | 2 | 66 | US | PLX-PAD, Placebo | Pluristem Ltd. | COVID, ARDS | 05/21 | 06/23 | | |
2020-001857-31: A clinical study to test if a drug called PLX-PAD is both safe and can help in the treatment of COVID-19 patients |
|
|
| Not yet recruiting | 2 | 40 | Europe, RoW | PLX-PAD, Dispersion for injection | Pluristem Ltd., Pluristem Ltd. | Pneumonia or Acute Respiratory Distress Syndrome (ARDS) caused by severe COVID-19 disease, COVID-19–related critical illness, Diseases [C] - Virus Diseases [C02] | | | | |
NCT03746899: Expanded Access for Treatment Use of PLX-PAD in Critical Limb Ischemia (CLI) |
|
|
| Available | N/A | | NA | PLX-PAD | WideTrial, Inc. | Critical Limb Ischemia (CLI) | | | | |
NCT03886506: Expanded Access Treatment of Subjects With Critical Limb Ischemia (CLI) With Minor Tissue Loss Who Are Unsuitable for Revascularization |
|
|
| Available | N/A | | US | PLX-PAD | Pluristem Ltd. | Critical Limb Ischemia (CLI) | | | | |
| placenta-based cell therapy / Charite - University of Medicine Berlin, Pluri |
| Recruiting | 2 | 0 | China | placenta-based cell therapy - Pluristem, Charite - University of Medicine Berlin | Pluristem, Charite - University of Medicine Berlin | COVID-19 | | | | |
